Developer docs
API playgroundTry for free, no card

Search company profiles

Kariya Pharmaceuticals

Full company profile

uuid00092l7

Namestring
Kariya Pharmaceuticals
Legal namestring
Kariya Pharmaceuticals ApS
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Kariya Pharmaceuticals is a privately-held Danish biotechnology company founded in 2018 and headquartered at the BioInnovation Institute in Copenhagen. The company is developing KP405, a first-in-class dual incretin receptor co-agonist that targets both the GLP-1 and GIP receptors, as a disease-modifying treatment intended to slow the progression of Parkinson's Disease, with potential application in Alzheimer's Disease. KP405 has demonstrated clear superiority over existing single-receptor incretin therapies in multiple animal models of neurodegeneration and is currently Phase I ready, having completed toxicology studies under full Good Laboratory Practice (GLP) compliance in line with FDA and EMA requirements.

The company's technology platform is based on the well-established incretin biology linking GLP-1/GIP receptor activation to neuroprotective effects, including improved synaptic plasticity, induction of neurogenesis, normalization of growth factor signaling, reduction of neuroinflammation, and promotion of mitochondrial biogenesis. Clinical proof-of-concept for the incretin approach in Parkinson's has been demonstrated by the GLP-1 analogue Exenatide. Kariya differentiates itself through the dual-receptor design and extensive preclinical characterization in neurodegeneration models.

Kariya Pharmaceuticals is a pre-commercial company generating no product revenue. Its business model is structured around advancing KP405 through clinical development with the goal of securing a pharmaceutical licensing deal, co-development partnership, or acquisition once the asset reaches a commercially attractive inflection point. The company is currently funded by the Novo Nordisk Foundation's BioInnovation Institute and Innovation Fund Denmark, and is operationally supported through its CEO's Executive-in-Residence role at Novo Holdings. The leadership team consists of CEO Ian Laquian (ex-Nycomed/Takeda CNS franchise builder) and CSO Dr. Christian Hölscher (neuroscience professor with 180+ publications in neurodegeneration). The company has 1-10 employees and targets a Parkinson's Disease patient population of 3.4 million people across the eight major markets, where no approved disease-modifying therapies currently exist.

Short descriptiontext

Kariya Pharmaceuticals is a Copenhagen-based pre-clinical biotech developing KP405, a first-in-class dual GLP-1/GIP receptor co-agonist designed to slow the progression of Parkinson's and Alzheimer's Disease, with a future revenue model centered on pharmaceutical licensing or acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, incretin receptor agonists, Parkinson's disease drugs, disease-modifying therapies, biopharmaceutical drug development
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurodegenerative Disease Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Licensing
TypeLicensing Royalties
Description

Pre-commercial biotech company developing disease-modifying drugs for neurodegenerative diseases. Revenue generation will likely come from licensing deals, co-development partnerships, or acquisition as the lead compound KP405 advances through clinical development toward regulatory approval and commercialization.

kariyapharma.com
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kariya Pharmaceuticals is developing KP405, a first-in-class dual incretin receptor co-agonist designed to slow the progression of Parkinson's Disease by improving synaptic plasticity and reducing neuronal degeneration through multiple neuroprotective mechanisms. The compound has completed GLP-compliant toxicology studies and is Phase I ready, intended for out-licensing or co-development with larger pharmaceutical companies as it advances through clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Efficacy demonstrated in multiple animal models of neurodegeneration with clear superiority over existing incretin therapies
Product overview1 text field

Kariya Pharmaceuticals is developing a single lead compound, KP405, as a first-in-class dual incretin receptor co-agonist disease-modifying drug for neurodegenerative diseases. The company's product pipeline centers on KP405, which targets Parkinson's Disease with potential applications in Alzheimer's Disease, and has achieved Phase I readiness following successful GLP-compliant toxicology studies.

Product and service1 record
1KP405
CategoryCore product - drug candidate
Description

KP405 is a first-in-class, dual incretin receptor co-agonist being developed to slow the progression of Parkinson's Disease. It targets both GLP-1 and GIP receptors to improve synaptic plasticity and reduce neuronal degeneration through multiple neuroprotective mechanisms, including neurogenesis, growth factor signaling normalization, reduced neuroinflammation, and mitochondrial biogenesis. KP405 has demonstrated clear superiority over existing incretin therapies in multiple animal models of neurodegeneration and is Phase I ready. The intended customers for the asset are large pharmaceutical companies seeking to license, co-develop, or acquire a Phase I-ready disease-modifying drug candidate for Parkinson's Disease.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing disease-modifying therapeutics for neurodegeneration, including Parkinson's and Alzheimer's. Most directly comparable to Kariya in therapeutic area, modality (engineered biologics/peptides), and clinical stage.

TypeDirect peer
Description

Late clinical-stage biotech developing protein immunotherapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in CNS therapeutic focus and biologics-based modality.

TypeDirect peer
Description

Commercial CNS specialty pharmaceutical company with Parkinson's Disease and neurology franchises. Comparable CNS-focused drug development and commercialization model, though larger and revenue-generating.

TypeDirect peer
Description

Biopharmaceutical company developing CNS therapeutics for neurological disorders. Comparable in CNS-focused small-molecule/biologic development and clinical-stage pipeline approach.

TypeDirect peer
Description

Clinical-stage biotech developing disease-modifying therapies for Alzheimer's Disease and other neurodegenerative disorders. Comparable in CNS pipeline focus, disease-modifying mechanism, and small-cap biotech profile.

TypeDirect peer
Description

Clinical-stage biotech developing disease-modifying therapeutics for Alzheimer's Disease and neurodegeneration. Comparable in CNS pipeline, mechanism-based approach, and small private/early-public biotech profile.

TypeEmerging player
Description

Clinical-stage company developing NLY01, a GLP-1 receptor agonist for Parkinson's Disease. Most directly comparable peer given the incretin mechanism overlap with Kariya's KP405 dual agonist approach.

TypeBroad incumbent
Description

Major pharmaceutical company developing tirzepatide (dual GLP-1/GIP agonist) for metabolic disease, with broader CNS programs including Alzheimer's. Comparable via its incretin franchise and CNS pipeline investment, though broader in scope.

TypeBroad incumbent
Description

Global leader in GLP-1 receptor agonists (semaglutide/Ozempic) with active CNS/neurodegeneration research programs. Comparable as the dominant incumbent in incretin therapeutics and a potential acquirer/partner for Kariya.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing therapeutics for CNS disorders and diabetes. Comparable in CNS pipeline focus and small-cap biotech profile with disease-modifying approaches.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kariya Pharmaceuticals

Neurodegenerative Disease Therapeuticskariyapharma.com

Kariya Pharmaceuticals is a Copenhagen-based pre-clinical biotech developing KP405, a first-in-class dual GLP-1/GIP receptor co-agonist designed to slow the progression of Parkinson's and Alzheimer's Disease, with a future revenue model centered on pharmaceutical licensing or acquisition.

What Kariya Pharmaceuticals does

Kariya Pharmaceuticals is a privately-held Danish biotechnology company founded in 2018 and headquartered at the BioInnovation Institute in Copenhagen. The company is developing KP405, a first-in-class dual incretin receptor co-agonist that targets both the GLP-1 and GIP receptors, as a disease-modifying treatment intended to slow the progression of Parkinson's Disease, with potential application in Alzheimer's Disease. KP405 has demonstrated clear superiority over existing single-receptor incretin therapies in multiple animal models of neurodegeneration and is currently Phase I ready, having completed toxicology studies under full Good Laboratory Practice (GLP) compliance in line with FDA and EMA requirements.

The company's technology platform is based on the well-established incretin biology linking GLP-1/GIP receptor activation to neuroprotective effects, including improved synaptic plasticity, induction of neurogenesis, normalization of growth factor signaling, reduction of neuroinflammation, and promotion of mitochondrial biogenesis. Clinical proof-of-concept for the incretin approach in Parkinson's has been demonstrated by the GLP-1 analogue Exenatide. Kariya differentiates itself through the dual-receptor design and extensive preclinical characterization in neurodegeneration models.

Kariya Pharmaceuticals is a pre-commercial company generating no product revenue. Its business model is structured around advancing KP405 through clinical development with the goal of securing a pharmaceutical licensing deal, co-development partnership, or acquisition once the asset reaches a commercially attractive inflection point. The company is currently funded by the Novo Nordisk Foundation's BioInnovation Institute and Innovation Fund Denmark, and is operationally supported through its CEO's Executive-in-Residence role at Novo Holdings. The leadership team consists of CEO Ian Laquian (ex-Nycomed/Takeda CNS franchise builder) and CSO Dr. Christian Hölscher (neuroscience professor with 180+ publications in neurodegeneration). The company has 1-10 employees and targets a Parkinson's Disease patient population of 3.4 million people across the eight major markets, where no approved disease-modifying therapies currently exist.

Kariya Pharmaceuticals firmographics

Firmographics
Name
Kariya Pharmaceuticals
Legal name
Kariya Pharmaceuticals ApS
Website
https://kariyapharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Kariya Pharmaceuticals is a Copenhagen-based pre-clinical biotech developing KP405, a first-in-class dual GLP-1/GIP receptor co-agonist designed to slow the progression of Parkinson's and Alzheimer's Disease, with a future revenue model centered on pharmaceutical licensing or acquisition.
Ownership category
akta.pro rank

Kariya Pharmaceuticals industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Incretin receptor agonists
  • Parkinson's disease drugs
  • Disease-modifying therapies
  • Biopharmaceutical drug development

Where Kariya Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Kariya Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Development and Licensing: Pre-commercial biotech company developing disease-modifying drugs for neurodegenerative diseases. Revenue generation will likely come from licensing deals, co-development partnerships, or acquisition as the lead compound KP405 advances through clinical development toward regulatory approval and commercialization.

Go-to-market motion1 record

Kariya Pharmaceuticals product offering

Product offering

Core offering

Kariya Pharmaceuticals is developing KP405, a first-in-class dual incretin receptor co-agonist designed to slow the progression of Parkinson's Disease by improving synaptic plasticity and reducing neuronal degeneration through multiple neuroprotective mechanisms. The compound has completed GLP-compliant toxicology studies and is Phase I ready, intended for out-licensing or co-development with larger pharmaceutical companies as it advances through clinical trials.

Product overview

Kariya Pharmaceuticals is developing a single lead compound, KP405, as a first-in-class dual incretin receptor co-agonist disease-modifying drug for neurodegenerative diseases. The company's product pipeline centers on KP405, which targets Parkinson's Disease with potential applications in Alzheimer's Disease, and has achieved Phase I readiness following successful GLP-compliant toxicology studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • KP405 KP405 is a first-in-class, dual incretin receptor co-agonist being developed to slow the progression of Parkinson's Disease. It targets both GLP-1 and GIP receptors to improve synaptic plasticity and reduce neuronal degeneration through multiple neuroprotective mechanisms, including neurogenesis, growth factor signaling normalization, reduced neuroinflammation, and mitochondrial biogenesis. KP405 has demonstrated clear superiority over existing incretin therapies in multiple animal models of neurodegeneration and is Phase I ready. The intended customers for the asset are large pharmaceutical companies seeking to license, co-develop, or acquire a Phase I-ready disease-modifying drug candidate for Parkinson's Disease.

Quantifiable outcome

  • Efficacy demonstrated in multiple animal models of neurodegeneration with clear superiority over existing incretin therapies

Companies that use Kariya Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Kariya Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Kariya Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Kariya Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Clinical-stage biotech developing disease-modifying therapeutics for neurodegeneration, including Parkinson's and Alzheimer's. Most directly comparable to Kariya in therapeutic area, modality (engineered biologics/peptides), and clinical stage.
  • Prothena Corporation: Late clinical-stage biotech developing protein immunotherapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in CNS therapeutic focus and biologics-based modality.
  • Acadia Pharmaceuticals: Commercial CNS specialty pharmaceutical company with Parkinson's Disease and neurology franchises. Comparable CNS-focused drug development and commercialization model, though larger and revenue-generating.
  • Sage Therapeutics: Biopharmaceutical company developing CNS therapeutics for neurological disorders. Comparable in CNS-focused small-molecule/biologic development and clinical-stage pipeline approach.
  • Cognition Therapeutics: Clinical-stage biotech developing disease-modifying therapies for Alzheimer's Disease and other neurodegenerative disorders. Comparable in CNS pipeline focus, disease-modifying mechanism, and small-cap biotech profile.
  • Alzheon: Clinical-stage biotech developing disease-modifying therapeutics for Alzheimer's Disease and neurodegeneration. Comparable in CNS pipeline, mechanism-based approach, and small private/early-public biotech profile.
  • vTv Therapeutics: Clinical-stage pharmaceutical company developing therapeutics for CNS disorders and diabetes. Comparable in CNS pipeline focus and small-cap biotech profile with disease-modifying approaches.

Emerging players

  • Neuraly (a D&J Company subsidiary): Clinical-stage company developing NLY01, a GLP-1 receptor agonist for Parkinson's Disease. Most directly comparable peer given the incretin mechanism overlap with Kariya's KP405 dual agonist approach.

Broad incumbents

  • Eli Lilly: Major pharmaceutical company developing tirzepatide (dual GLP-1/GIP agonist) for metabolic disease, with broader CNS programs including Alzheimer's. Comparable via its incretin franchise and CNS pipeline investment, though broader in scope.
  • Novo Nordisk: Global leader in GLP-1 receptor agonists (semaglutide/Ozempic) with active CNS/neurodegeneration research programs. Comparable as the dominant incumbent in incretin therapeutics and a potential acquirer/partner for Kariya.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Kariya Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Kariya Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kariya Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Kariya Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kariya Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kariya Pharmaceuticals

What does Kariya Pharmaceuticals do?

Kariya Pharmaceuticals is developing KP405, a first-in-class dual incretin receptor co-agonist designed to slow the progression of Parkinson's Disease by improving synaptic plasticity and reducing neuronal degeneration through multiple neuroprotective mechanisms. The compound has completed GLP-compliant toxicology studies and is Phase I ready, intended for out-licensing or co-development with larger pharmaceutical companies as it advances through clinical trials.

Is Kariya Pharmaceuticals a public or private company?

Kariya Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kariya Pharmaceuticals founded?

Kariya Pharmaceuticals was founded in 2018. It employs 1 to 10 people.

Where is Kariya Pharmaceuticals based?

Kariya Pharmaceuticals is headquartered in Copenhagen, Denmark, in the Europe region.

How does Kariya Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Development and Licensing.

Who are Kariya Pharmaceuticals's main competitors?

Direct peers on record are Denali Therapeutics, Prothena Corporation, Acadia Pharmaceuticals, Sage Therapeutics, Cognition Therapeutics, Alzheon and vTv Therapeutics. Neuraly (a D&J Company subsidiary) is listed as an emerging player. Broad incumbents are Eli Lilly and Novo Nordisk.

Does Kariya Pharmaceuticals have an API?

No public API is recorded for Kariya Pharmaceuticals.

What industry is Kariya Pharmaceuticals in?

Kariya Pharmaceuticals's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureCan GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depressionPharmaceutical companies are developing GLP-1-related compounds for addiction and brain disorders, with Eli Lilly presenting brenipatide results for alcohol use disorder and Kariya Pharmaceuticals sharing KP405 data for Parkinson's disease. Baseline Therapeutics plans phase III trials of BT-001 in early 2027. Researchers expect industry trials to accelerate access and potentially lead to FDA approvals.Longevity.TechnologyCould GLP-1s become brain longevity drugs?Kariya Pharmaceuticals and NeuraLight announced a partnership to test KP405, a GLP-1 drug engineered to cross the blood-brain barrier, for Parkinson's and Alzheimer's. The company has completed Phase I safety testing and is preparing Phase II trials, while NeuraLight's biomarker platform will measure brain function. The partnership reflects a shift in longevity science toward preserving cognitive function.BioSpaceKariya and NeuraLight Partner to Measure How Next-Generation GLP-1 Therapies Impact the BrainKariya Pharmaceuticals and NeuraLight announced a partnership to integrate NeuraLight's brain function biomarker platform into Kariya's Phase II trial of KP405, a brain-penetrant dual GLP-1/GIP agonist for Parkinson's and Alzheimer's. The collaboration aims to quantify neuroprotective effects, following prior GLP-1 trials that failed due to insufficient brain penetration.LinkedInNeurology M&A: Is it a hot target now?Kariya Pharmaceuticals announced the successful completion of a Phase I clinical trial for KP405, a brain-penetrating dual GLP-1/GIP receptor agonist designed to treat Parkinson's disease. The study, conducted by strategic partner MAC Clinical Research in the UK, demonstrated that the drug is safe and well-tolerated across 88 participants. Kariya plans to advance KP405 into Phase II trials next year, positioning it as a potential first-to-market treatment in this emerging drug class.